Previous 10 | Next 10 |
home / stock / vrtx / vrtx articles
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over Penumbra, Inc. (NYSE: PE...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 12.82% on an annualized basis producing an average annua...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.13% on an annualized basis producing an average annual...
In a significant trend, pharmaceutical companies in the U.S. introduced new drugs last year at prices 35% higher than in 2022, notably attributed t...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 5.51% on an annualized basis producing an average annual ...
Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (vanz...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (vanza triple) pro...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...